Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025

Dogwood Therapeutics, Inc.

2025-Q1 EPS reported -$8.45

Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).
Cash $14.8M at Dec 31, 2024; $4.8M capital raise and conversion of $19.5M debt to equity extend runway through Q1 2026.
Halneuron Phase 2b CINP trial dosing commenced; interim data readout expected Q4 2025.
Largest shareholder converted $19.5M loan to equity, strengthening balance sheet.
Exploring partnerships for IMC-2 (Long-COVID) and IMC-1 (fibromyalgia); update on IMC-1 expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.